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I nhaled corticosteroids are widely used as effective first-linetreatments for various chronic respiratory illnesses, includingasthma, cystic fibrosis, and allergic rhinitis.1 Although the
long-term use of ICSs has a more favorable safety profile than oral
corticosteroids, uncertainty about systemic complications persist.
In children, the long-term use of oral corticosteroids can lead to
compromised linear growth and bone mineralization, diabetes
mellitus (types 1 and 2) (DM), Cushing syndrome, obesity, and sup-
pression of the hypothalamic-pituitary-adrenal (HPA) axis. Inhaled
corticosteroids have a similar adverse effect profile but with less
frequency and severity. We review the endocrine effects of ICSs
in children and the properties of the various formulations as
they relate to these adverse outcomes. We have provided grading
of the evidence associated with our conclusions and recommen-
dations based on guidelines from the Centre for Evidence Based
Medicine, in which a lower number indicates better evidence
(scale, 1-5), and A is the highest grade of recommendation (scale,
A-D).2
Case Presentation
A 7-year-old girl presented with altered mental status and a new-
onset seizure. She was well until that day, when she developed
cough, fatigue, and fever and then had a generalized seizure.
When the ambulance arrived, her blood glucose level was 24
mg/dL (to convert to millimoles per liter, multiply by 0.0555). In
the emergency department, her blood pressure was 85/50 mm
Hg, and her pulse was 125/min. The results of head imaging and a
full sepsis workup were normal. Her medical history was signifi-
cant for asthma and seasonal allergies. At home she took a regi-
men of fluticasone propionate dry powder inhaler (two 110-μg
puffs twice daily), salmeterol xinafoate (21 μg/d), albuterol sulfate
as needed, and cetirizine (10 mg/d) to which she was adherent.
She had a 5-day course of prednisone 4 months prior. Her growth
was normal.
She had a sodium level of 140mEq/L (to convert to millimoles
per liter, multiply by 1), and her potassium level was 4 mEq/L (to
convert to millimoles per liter, multiply by 1). A serum cortisol level
at the time of the hypoglycemia was low (2.1 μg/dL) (to convert to
nanomoles per liter, multiply by 27.588). Further testing revealed a
morning cortisol level of 0.8 μg/dL and an adrenocorticotropic
hormone (ACTH) level less than 5 pg/mL (to convert to picomoles
per liter, multiply by 0.22), suggesting central adrenal insufficiency
(AI). A low-dose 1-μg ACTH stimulation test confirmed AI with a
peak cortisol level of 1.4 μg/dL (reference range, >18 μg/dL). Thy-
roid function test results, insulin-like growth factor 1 (IGF-1) levels,
and prolactin levels were normal. Maintenance hydrocortisone
treatment was initiated, and the family received stress dose corti-
costeroid education. Her pulmonologist reduced the inhaled corti-
costeroid (ICS) dose to 330 μg/d after adding montelukast, and
the asthma remained well controlled. The hydrocortisone dose
was gradually weaned and hydrocortisone use discontinued. Six
months later, an additional low-dose ACTH stimulation test result
was normal with a peak stimulated cortisol level of 19.9 μg/dL. The
HPA axis suppression was attributed to her ICSs.
Inhaled corticosteroids (ICSs) are widely used as first-line treatment for various chronic
respiratory illnesses. Advances in devices and formulations have reduced their local adverse
effects. However, as delivery of ICSs to the lungs improves, the systemic absorption
increases, and an adverse effect profile similar to, althoughmilder than, oral corticosteroids
has emerged. Themost serious potential adverse effect is adrenal insufficiency, which can be
life threatening. Adrenal insufficiency occurs most in patients taking the highest doses of ICSs
but is reported with moderate or even low doses as well. Our recommendations include
greater vigilance in testing adrenal function than current standard practice. In patients with
diabetes mellitus (types 1 and 2), an increase in glucose levels is likely, and diabetes
medication adjustment may be needed when initiating or increasing ICSs. The risk of linear
growth attenuation and adverse effects on bonemineral density is generally low but should
be considered in the face of additional risk factors. On behalf of the Pediatric Endocrine
Society Drugs and Therapeutics Committee, we present a review of the endocrine adverse
effects of ICSs in children and offer recommendations relating to testing and referral. Limited
data in particular realms diminish the strength of certain recommendations, and clinical
judgment continues to be paramount.
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Dose and Formulation Effects of ICSs
Primary Conclusions
Clinical effectiveness and systemic absorption have a strong posi-
tive correlation that can only be partially addressed by device and
formulationmodifications (level of evidence 1).
Primary Recommendations
Device advancements have reduced local adverse effects. How-
ever, reducing the systemic adverse effects of ICSsmay require in-
creasing protein binding and rapid clearance time and decreased
lipophilicity (grade of recommendation A).
Pharmacodynamics and pharmacokinetics vary among ICS
formulations. This is a result of differences in oral bioavailability,
glucocorticoid receptor affinity, variable deposition in the lung,
volumes of distribution, lipophilic qualities, rates of clearance, and
modes of delivery.1,3
There are a variety of ICS delivery devices, including metered-
dose inhalers,drypowder inhalers, andnebulizers;metered-dose in-
halers are often used with spacer devices that reduce oral deposi-
tion and increase lungdelivery.Oral deposition and lungdelivery are
alsoaffectedbyparticlesize,withsmallerparticleshaving lessoraland
greater lung deposition.4 Local adverse effects, such as candidiasis,
dysphonia, pharyngitis, and cough, areminimizedwith proper inha-
lation technique and postinhalation oropharyngeal rinsing. Com-
pounds with a high rate of first-pass metabolism have less systemic
drug effect fromoral deposition than thosewith lower rates.5
Theclinicallyefficacious ICSdeposited inthe lung isalsothemain
source for systemic absorption5,6; therefore, improved lung deliv-
ery of ICS actually increases the risk of endocrine adverse effects.
Although the shift from chlorofluorocarbons to hydrofluoroalkane
allows smaller particle sizes andbetter lungdelivery formany com-
pounds, it can also result in greater systemic absorption.7
There are variable degrees of cortisol suppression or systemic
bioavailability among delivery devices8-10; however, for most ICSs,
respiratoryeffectivenesscorrelateswithsystemicbioavailability.De-
vices that result in greater lung deposition should thus be used at
lower doses. Postulation regarding the effect of discrepant in-
tralungabsorptionhas arisen, for example,whether there is greater
systemic absorption fromalveoli than bronchi, but data in this area
are lacking.4 What appears clear, however, is that in healthy lungs
or healthier asthmatic lungs, absorption is greater than in states of
active disease and airflow obstruction, hence supporting clinical
guidelines advocating step-down therapy for those who achieve
asthma control.11,12
Compounds or metabolites that are more tightly bound to al-
bumin and other proteins and less systemically active have fewer
adverse effects, as do those cleared from the circulationmore rap-
idly. Although not well investigated, some experts13 assert that in-
creased lipophilicity leads to greater systemic adverse effects be-
cause ofwider distribution and slower clearance, particularly in the
case of fluticasone. Thus, although efforts to reduce oral deposi-
tion have resulted in fewer local adverse effects, the effort to re-
duce systemic adverse effects may ultimately need to focus on in-
creasing protein binding, more rapid clearance, and decreasing
lipophilicity.Bindingandclearancedata for commonlyused ICSsare
summarized in Table 1.14
The compound ciclesonide hydrofluoralkane14 is converted to
ametabolite thathasahigh first-passmetabolismrate, is highlypro-
tein bound, is rapidly cleared, and thus would be expected to de-
liver clinical effect at the lungswhile resulting in lower systemic con-
sequence. However, experience with ciclesonide is not as long
standingor aswidespreadaswith fluticasoneproprionatedrypow-
der inhaler, and it tookmany years of clinical use for endocrine ad-
verse effects of fluticasone to surface.13-15 Thus, although thephar-
macodynamic profile of ciclesonide appears to be promising,
cautious optimism is recommended.
Effects on the HPA Axis
Primary Conclusions
TheHPAaxis suppression, although rare, is themost seriouspoten-
tial ICS adverse effect and can occur even in children taking stan-
dard dosages (level of evidence 1).
At a Glance
• Inhaled corticosteroids (ICSs) are widely used as effective
first-line treatment for various chronic respiratory illnesses.
Although the long-term use of ICSs has a more favorable safety
profile than that of oral corticosteroids, uncertainty about
systemic complications persists.
• With the advancement of devices and in drug pharmacokinetics,
lung delivery and bioavailability of ICSs have improved, and an
adverse effect profile similar to oral corticosteroids is emerging,
albeit milder and with less frequency.
• Hypothalamic-pituitary-adrenal axis suppression is a potentially
life-threatening adverse effect of ICSs. Adrenal function should
be tested in symptomatic patients, those with growth
attenuation, and high-risk asymptomatic patients.
• Data on linear growth and bonemineral density (BMD) are
generally reassuring, but height attainment should be carefully
monitored, and testing for BMD should be considered in
high-risk patients. Deteriorating blood glucose level control in
patients with preexisting diabetes mellitus (types 1 and 2) (DM)
is commonwith ICSs, and DMmedication dose adjustments are
likely required at the initiation of ICS treatment and with ICS
dose increases.
Table 1. Pharmacodynamics and Pharmacokinetics of Commonly Used Inhaled Glucocorticoid Formulationsa
Inhaled Glucocorticoid
Oral
Bioavailability, %
Particle
Size, μm
Protein
Binding, %
Systemic
Clearance, L/h
Beclomethasone dipropionate hydrofluoroalkane 20/40b <2.0 87 150/120b
Budesonide DPI 11 >2.5 88 84
Ciclesonide hydrofluoroalkane <1/<1b <2.0 99/99b 152/228b
Fluticasone propionate DPI ≤1 2.8 90 66
Abbreviation: DPI, dry powder
inhaler.
a Adapted from Ahmet et al.14
bActive metabolite.
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Primary Recommendations
Children taking ICSs with hypoglycemia or altered mental status
should be urgently evaluated for adrenal insufficiency and treated,
ifnecessary (gradeof recommendationA).Childrenwithgrowth fail-
ure, anorexia, or weight loss should be tested for AI (grade of rec-
ommendation B). Children taking high-dose ICSs or those requir-
ing periodic oral corticosteroids treatment or additional long-term
intranasal corticosteroid treatment, especially in conjunction with
a low bodymass index (BMI) (calculated as weight in kilograms di-
videdbyheight inmeterssquared), shouldbetestedroutinely (grade
of recommendation C).
A testing algorithm is outlined in Table 2 and described in the
textbelow.Stimulation testing interpretation is level of evidence 1b,
as ismaking a diagnosis of AI fromamorning cortisol level less than
3 μg/dL in a symptomatic patient.
Assuranceof adrenal sufficiency inasymptomaticpatientswith
amorning cortisol level greater than 10μg/dL is level of evidence 5,
expert opinion. Thus, if suspicion is high, one should not rely solely
on adequate morning cortisol values.
It is well known that oral and injectable corticosteroids can re-
sult in suppression of theHPAaxis andwith prolongeduse can lead
to adrenocortical atrophy. After the introductionof corticosteroids
in the late 1940s to treat rheumatoid arthritis, reports of sudden
deaths after surgery began to emerge.16 When ICSs were intro-
duced for asthma control, HPA axis suppressionwas thought to be
rare but still a consideration when used at high doses for a pro-
longed period.17,18 Reassuring studies19,20 did not have evidence of
AI at standard doses of ICSs.
In a meta-analysis21 examining the adverse effects of ICSs, no
evidence of AI with ICS doses at 400 μg/d or less was found, re-
gardlessof thedrug.Athigherdoses, theriskofAIwas increased17,18,21
and commonwhen growth suppression was also present.13,22
Since then, however, there have also been reports of AI occur-
ringevenat lowerdoses. Patel et al22 described8childrenwhopre-
sented with AI despite 7 of these children being prescribed a stan-
dard recommendeddoseof ICS.Twopresentedwithhypoglycemia,
both without a history of abrupt cessation of ICS or illness; several
children also had poor weight gain.13,22 In another case, a 7-year-
old boy who presented in an acute adrenal crisis had been treated
with fluticasone at a typically prescribed dose of 220 μg/d for sev-
eral years.13
As cases of AI associated with ICSs became increasingly re-
ported, a survey was sent to pediatricians and endocrinologists in
the United Kingdom to investigate the frequency of acute adrenal
criseswith ICS use.13 Thirty-three patients (28 children)were iden-
tified: 23 patients presented with hypoglycemia, including 13 with
decreased level of consciousness or comaand9with comaand sei-
zures (1with comaandseizure laterdied).Most cases involvedhigh-
dose ICSs that were still within recommended guidelines for se-
verepersistentasthma.13 Inasimilar survey fromFrance,46patients
with AI were identified, of whom 18% were not receiving high-
dose ICSs.23
It is important to acknowledge the lack of testing standardiza-
tion across studies.24 In cases of secondary or central AI fromexog-
enous corticosteroid use, the adrenal cortex lags behind the pitu-
itary gland in the recovery process.25 Therefore, although a basal
Table 2. Adverse Effects of ICSs
Adverse Effect
Patients at
Highest Risk Signs and Symptoms Testing and Action
Test Result
Interpretation
Growth suppression All patients taking
ICSs and additional
growth-impairing
medications
Decrease of >2 SDs in
height or retarded
growth velocity
below age and
pubertal norms
(persisting after
1 year of therapy)
Refer to a specialist Not applicable
Adrenal insufficiency Symptomatic
patients And
asymptomatic
patients with risk
factors: high daily
dose, taking an
ICS and another
corticosteroid, or
low BMI
Cushingoid features,
anorexia, weight
loss, fatigue, growth
failure, or
hypoglycemia;
typical symptoms of
chronic adrenal
insufficiency may not
occur; hence, also
test all high-risk
asymptomatic
patients
Symptomatic: if
morning cortisol levela
<3 μg/dL, adrenal
insufficiency is likely;
if morning cortisol level
≥3 μg/dL, 1-μg ACTH
stimulation test
Asymptomatic but at
high risk: if morning
cortisol level <3 μg/dL,
1-μg ACTH stimulation
test; if morning cortisol
level 3-10 μg/dL, refer
to a specialist
A stimulated cortisol
value <18 μg/dL is
abnormal
Hyperglycemia or
diabetes mellitus
(types 1 and 2)
Patients with risk
factors or signs of
insulin resistance
taking high daily
dose
Polyuria, polydipsia Annual hemoglobin A1c
levels and fasting
glucose
Refer to a specialist
if hemoglobin A1c
≥6.0% or fasting
glucose >100 mg/dL
Worsening blood
glucose level control
in diabetes mellitus
(types 1 and 2)
Patients with
diabetes mellitus
after ICS treatment
is initiated or if dose
is increase
Worsening blood
glucose control
Adjust diabetes
medications
Not applicable
Decrease in bone
mineral density
Chronic disease,
malnutrition, or
taking long-term
medications that
reduce bone mineral
density
Generally
asymptomatic
No routine testing
unless at high risk;
if not at high risk,
400- to 800-IU vitamin
D supplementation and
ensure adequate
calcium intake
Higher-dose vitamin D
supplementation for
levels <30 ng/mL
Abbreviations: ACTH,
adrenocorticotropin hormone;
BMI, bodymass index; ICS, inhaled
corticosteroid.
SI conversion factors: To convert
cortisol to nanomoles per liter,
multiply by 27.588; glucose to
millimoles per liter, multiply by
0.0555; vitamin D
(25-hydroxyvitamin D) to nanomoles
per liter, multiply by 2.496.
a Morning cortisol level is defined as a
serum cortisol level measured
between 7 and 9 AM.
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cortisol level may be normal in a child treated with an ICS, it does
not ensure a sufficient cortisol increase in the setting of stress or
illness.26 The lack of uniform testing for AI has resulted in inconsis-
tent and conflicting conclusions.26
In accordance with these concerns, Zöllner27 searched the lit-
erature for studiesof children treatedwith ICSswhowere tested for
AI with dynamic adrenal function test results. Only 4 studies were
identified.19,28-30 Using dynamic adrenal testing, those studies
sought to determine the prevalence of HPA axis suppression
in 26 children with asthma treated with ICSs and intranasal
corticosteroids.31 With hypocortisolemia defined as a basal morn-
ing cortisol level less than 3 μg/dL, none of the children had a low
basal cortisol level.However,metyrapone testing revealed that35%
had HPA axis suppression; this test is now difficult to perform be-
causeof theunavailabilityof this agent.A larger study32by thesame
groupfoundthat6%hadhypocortisolemia, thedegreeofbiochemi-
cal suppressioncanoccur inupto two-thirdsof children treatedwith
corticosteroids, and suppression may even occur at low doses. An
older study29 identified a morning ACTH level less than 11.7 pg/mL
tocorrelatewithAIonstimulationtesting,but largerstudies28,30,33,34
did not corroborate this finding.
Concomitant nasal corticosteroid use, low BMI, and cumulative
dose of ICS are contributing factors to the development of HPA axis
suppression.31,32Growth failure is a late findingand isnothighly sen-
sitivefordetectingHPAaxissuppression.30Thus,practitionersshould
testmostat-riskpatientsbeforegrowthfailureoccurs.However,when
growth failure is detected,HPAaxis function should be tested.22,35
Poor adherence to ICS treatment has a protective effect, likely
due to partial recovery and incomplete suppression of the adrenal
glands.32 However, poor adherence also likely conversely leads to
poorer asthma control and additional oral corticosteroid doses.
Our recommendations, as summarized in Table 2, include test-
ing cortisol levels between 7 and 9 AM in all symptomatic patients
not in crisis. If themorning cortisol level is less than 3 μg/dL, a diag-
nosis of AI ismade.However, if themorning cortisol level is 3 μg/dL
or greater, an ACTH stimulation test is required. Symptoms of AI in
patients taking ICSs are similar to those seen with other forms of
ACTH insufficiency, including anorexia, weight loss, growth failure,
and hypoglycemia; unique to these cases are possible signs of ap-
parent corticosteroid excess, such as cushingoid features.
Symptomsof adrenal crisis, such ashypotension, lethargy, and
hypoglycemia, should provoke immediate testing, including a cor-
tisol level in all cases and stimulation testing when possible. If the
patient is unstable or ill appearing, treatment with stress doses of
corticosteroids should be prompt while awaiting results.
Wealso recommendtesting in certain categoriesof asymptom-
atic patients taking ICSs, including those takinghighdaily ICSdoses
or an ICSwithother systemically absorbedcorticosteroids, particu-
larly patients with low BMI. The 10-μg/dL threshold is acknowl-
edgedbyourgroupassomewhatarbitrary;however, it iswidelyused
in clinical practicebyendocrinologists. Referral for stimulation tests
on all at-risk patients is impractical. With this in mind, high-risk pa-
tients should be monitored for symptoms of AI even with reassur-
ing morning cortisol levels.
We acknowledge that although the 1-μg ACTH test is not defi-
nitely superior to the standard 250-μg ACTH stimulation test, it is
generally regardedasmoresensitive forsecondary (central)HPAaxis
suppression.36 At aminimum, baseline and 30-minute cortisol val-
ues should be measured, although sampling at more frequent in-
tervals increases testing reliability (ie, 10-, 15-, 20-, and 25-minute
samples).37 A peak cortisol level below 18 μg/dL indicates AI.38
When HPA axis suppression from ICS use is detected in symp-
tomatic patients, daily treatmentwith corticosteroids are required.
Inmilder or asymptomatic cases, treatmentmay be needed only in
the settingof illnessorphysical stress.All casesofHPAaxis suppres-
sion should be referred to an endocrinologist, and these patients
should followupcloselywith theirpulmonologistor allergist for con-
siderationof ICSdose reduction if safe, possiblybyaddinga cortico-
steroid-sparing agent (ie, leukotriene receptor antagonists).
Effects on Linear Growth
Primary Conclusions
In most patients, ICSs have minor and short-term effects on
growth and very mild but potentially persistent long-term effects
(level of evidence 2) (few studies followed through to final height
attainment).
Primary Recommendations
Theminor growth risks are outweighed by the respiratory benefits
of ICSs (grade of recommendation B). Patients at higher risk in-
clude those using additional growth-impairingmedications (grade
of recommendation D) (primarily based on expert opinion).
Oral corticosteroids impair linear growth through suppression
of growth hormone secretion, down-regulating the growth hor-
mone receptor, reduction of IGF-1 concentration, and suppression
of collagen synthesis at the growth plate.39
The effect of ICSs on linear growth has been evaluated via
knemometry, a technique that measures the distance from the sur-
faceof the right flexedknee to thebottomof the sole and is aprecise
method of monitoring short-term growth.40-42 A placebo-
controlled, crossover trial found a reduction in growth by 32% after
2 weeks of budesonide dry powder inhaler therapy.41 Similar meth-
ods have been used to reveal growth reduction with short-term
therapy with other ICSs, including fluticasone and beclomethasone
dipropionate hydrofluoroalkane.42-44 Ciclesonide, thus far, has not
beenfoundtocausemajorgrowth impairmentusingknemometry.43
Intermediate-terminvestigationsof theeffectof ICSsongrowth
have foundmild impairment.Using inhaledchlorofluorocarbonand
beclomethasone dipropionate dry powder inhaler at 200 μg twice
daily, the Dutch Pediatric Asthma Study Group45 found a signifi-
cant but small reduction in height (−0.28 SD) in 1 year. A subse-
quent study46 found thatdoubling thedoseof chlorofluorocarbon-
beclomethasone dipropionate dry powder inhaler (400 μg twice
daily) hadamore significant effectonheight (−0.27SD) thana stan-
dard chlorofluorocarbon-beclomethasone dipropionate dry pow-
der inhaler dose (200μg twice daily; −0.16 SD) for 1 year, and there
was no added benefit. Of note, there was a disparity in the results
at thesamedose fromthesamegroup,perhapshighlighting thevari-
able short-term effects of ICSs on growth.
Ina large,prospective,open-label studyofbothbudesonideand
fluticasone,Anthracopoulos et al47 foundgrowth reduction inboth
groups in the first 6 to 12months (−0.08SD),whichwas consistent
with previous studies.48,49 However, patients’ heights returned to
the baseline by 24 and 36months.
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Adult height is arguably the most critical outcomemeasure of
ICSsuppressiveeffectongrowth.Most long-termstudies43,50,51have
found that adult heights in treated children and nontreated asth-
matic control patients did not differ significantly. However, few
studies52,53 have found aminor effect on final height of 1 cm.
Effects on BoneMineral Density
Primary Conclusions
Inhaled corticosteroids have mild effects on bone mineral density
(BMD) that usually do not reach the threshold of clinical signifi-
cance (level of evidence 2). Measures to ensure vitamin D suffi-
ciency may ameliorate the negative BMD effects of ICSs (level of
evidence 4).
Primary Recommendations
Routinedual-energyX-rayabsorptiometry screening inchildren tak-
ing ICSs without other major risk factors is not indicated (grade of
recommendationB).Measures toensurevitaminDandcalciumsuf-
ficiencyare indicatedand in lower-riskpatients taking ICSsentail rou-
tine vitaminD supplementation of 400 to800 IU/dwithoutmoni-
toring vitamin D levels in blood (grade of recommendation C).
Several mechanisms impair both gastrointestinal absorption
tract and renal tubular reabsorptionof calcium, resulting in second-
ary hyperparathyroidism.54 Furthermore, corticosteroids sup-
pressgonadotropin-releasinghormoneand inhibitbothgrowthhor-
moneand IGF-1 secretionandgrowthhormoneand IGF-1 axis action,
synergistically reducingBMD.Ofnote, corticosteroid-inducedbone
mineral loss occurs mainly in trabecular bone, such as the spine.39
The threshold dose of ICSs for bone mineral loss has not been
conclusively defined. Most pediatric studies55-58 evaluated the ef-
fects of ICSs on lumbar spine BMD by dual-energy X-ray absorpti-
ometry.A2003meta-analysis59of6studiesofadults includedatotal
of 635 asthmatic patients using 4 different ICSs for at least 3 years.
This analysis did not reveal a significant difference (−4.1%, P = .80)
in lumbar BMD in patients vs controls.
Assessment of the effects of ICSs on BMD in children is con-
founded by variable bone accretion associated with linear growth
and age at entry into puberty.60 Several studies60-63 have looked
at younger children to minimize the confounder of puberty. Three
studies60-62 found no deleterious effects of standard doses of
beclomethasone or fluticasone on BMD in children 12 years and
younger. However, a study63 of 48 prepubertal children using
high-dose beclomethasone or budesonide (mean [SD] dose, 670
[480] μg/m2 daily) found a dose-dependent decrease of lumbar
spine BMD accrual in 1 year in treated patients; of note, those tak-
ing oral corticosteroids were not excluded, and the study did not
calculate CIs.
A study64 evaluating BMD in 37 adolescents (mean [SD] age,
13.6 [3.3]years) treatedwithhigh-dosefluticasonepropionate(mean
[SD]dose, 770 [250]μg/m2daily) for amean (SD)of 2.9 (1.6) years
revealed that lumbar BMD was more than 1 SD below the mean in
35% of treated patients compared with controls (P = .001). How-
ever, when correcting for bone age, this value decreased to 16%,
which was no longer statistically significant.
Overall, children receiving high-dose ICSs are at risk for sub-
stantially diminished BMD if they also have concomitant risk fac-
tors, such as frequent oral corticosteroids, malnutrition, or chronic
disease. There is some evidence that optimizing vitamin D in chil-
dren taking ICSs can ameliorate this effect.55,65 Thus, although the
role of routinemonitoring and titration of vitamin D supplementa-
tion is not yet established, our group considers it advisable for this
group at highest risk.
For those taking ICSs without a compounding risk, routine se-
rum vitamin D level determination is not needed. Clinicians should
be cognizant of adequate vitamin D intake, prophylactically pro-
vide400to800IU/dofvitaminD,andensureadequatedietarycal-
cium of 1000 to 1300mg/d.66
Effects of Inhaled Corticosteroids
on Glucose Metabolism
Primary Conclusions
The effects of ICSs on glucose levels are dose dependent. The
effects of ICSs on glucose levels are primarily of concern in
patients who have a previous diagnosis of DM or are at high risk of
type 2 DM. These 2 conclusions are of evidence level 4 primarily
because pediatric studies are limited. Data from adults in these
areas are stronger.
Primary Recommendations
Patients with DM in whom ICSs are initiated or increased may
require changes to their DM medication regimen. Patients at high
risk of developing type 2 DM from obesity compounded by
another risk factor, such as ethnicity and/or a positive family his-
tory, should be tested after ICS treatment is initiated or increased.
Testing for DM is generally recommended for this population
regardless of whether they are taking ICSs (grade of recommenda-
tion D). These recommendations are primarily regarded as expert
opinion because pediatric studies are limited, although adult data
are stronger.
Themetabolic effects of corticosteroids include decreased in-
sulin sensitivity in several tissues.67 The decrease in insulin-
stimulated glucose uptake in skeletal muscle is mediated through
glucocorticoid-inducedpostreceptoreffects.68Corticosteroidsalso
cause an increase in hepatic glucose production69 as reported by
Pagano et al70; under the influence of treatment with high-dose
glucocorticoid, there was an increase in hepatic glucose produc-
tion evident in both the fasted and postprandial states. However,
this glucogenic effect of corticosteroids couldbeovercomebyhigh
concentrations of insulin, whereas skeletal muscle glucose uptake
wasdiminished. Therefore, peripheral insulin resistance appears to
be the predominant mechanism leading to corticosteroid-induced
hyperglycemia. It has also been suggested that islet cell toxic ef-
fects and apoptosis occur in patients exposed to corticosteroids.71
Furthermore, corticosteroids are known to inhibit insulin secretion
by pancreatic β-cells.72
Inhaled corticosteroids have been implicated in contributing
to clinical hyperglycemia and DM. Most studies examining this
effect have been conducted in adult populations. For example, a
study69 performed in a large Veterans Affairs population sug-
gested that, although ICSs were not associated with hyperglyce-
mia in individuals without DM, among people with DM, ICS use
was correlated with glucose levels in a dose-dependent manner. A
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number of small studies of adults73,74 have similarly linked hyper-
glycemia among diabetic individuals, but not individuals without
DM, to ICS use.
Ofnote,anumberof investigations75,76havesuggestedthat ICSs
can induce insulin resistanceamong individualswithoutDM.A large
epidemiologic study77 fromCanada identifieda34%to64%higher
incidenceofnew-onsetDMamongthosetaking ICSs,aswellasa34%
to54%higher rateofprogression to insulinuseamongpatientswith
established DM taking ICSs, although the researchers did not ad-
just for BMI. Both these studies established a dose-response asso-
ciationbetween ICSandbloodglucose levels,withdailydoses inex-
cessof 1000μgof fluticasonepropionatedrypowder inhalerhaving
themost pronounced effect.
The only pediatric study78 to date examining glycemic effects
of ICSs reported a small but statistically significant increase in he-
moglobin A1c levels in children with asthma who were taking ICSs.
However, the study failed to identify a dose-response association
between ICSs and glucose levels. Furthermore, the only study79 to
examine theeffects of asthma treatmenton childrenwithpreexist-
ingDMcontained an insufficient number treatedwith ICSs to draw
meaningful conclusions.
Our recommendationswith regard to theeffectsof ICSsonglu-
cose metabolism are summarized in Table 2. They include adjust-
ing DM medications as needed when ICS use is initiated or ad-
justed. For children without DM, our recommendations include
testing those at risk because of obesity compounded by an addi-
tional factor, such ashigh-risk ethnic groupor family history of type
2 DM. Evidence about levels of fasting glucose and hemoglobin A1c
thresholds placing children into a higher DM risk category contin-
ues tobe apoint of debate; however, our teamhas chosen a fasting
glucose levelof 100mg/dLandahemoglobinA1c levelof6.0%based
on available data.80,81
Conclusions
Inhaledcorticosteroidsaregenerallysafe,effectivedrugs,butadverse
endocrineeffectsmayoccur.Althoughadverseeffectsandthethresh-
olds defined as high dose by asthma guidelines do not precisely cor-
relate, forthesakeofclinicalpractice,highdoseforanyparticularcom-
poundissimilar tothatdefinedbytheNationalAsthmaEducationand
PreventionProgram.82Wesummarizedosingguidelines inTable3.We
agree with the step-up and step-down approach put forth in these
guidelines,82meaningthatpatientswithpoorasthmacontrolneedan
increase in dosing, followed by reductions in dosingwhen adequate
asthmacontrol isachieved.Wedonotrecommenddecreasingthe ICS
doseif it isdeemednecessarytopreventpulmonaryexacerbationsand
recurrent treatmentwith oral corticosteroids.
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Table 3. Categorization of Daily Doses of Inhaled Corticosteroidsa
Corticosteroid
Daily Dose by Age, y
Low Medium High
0-4 5-11
>12 to
Adults 0-4 5-11
>12 to
Adults 0-4 5-11
>12 to
Adults
Beclomethasone dipropionate
hydrofluoroalkane
(40 or 80 μg per puff), μg
NA 80-160 80-240 NA >160-320 >240-480 NA >320 >480
Budesonide
DPI (90, 180, or
200 μg), μg
NA 180-400 180-600 NA >400-800 <600-1200 NA >800 >1200
Inhaled (inhaled
suspension), mg
0.25-0.5 0.5 NA >0.5-1.0 1.0 NA >1.0 2.0 NA
Funisolide
Standard (250 μg
per puff), μg
NA 500-750 500-1000 NA 1000-1250 >1000-2000 NA >1250 ≥2000
Hydrofluoroalkane
(80 μg per puff), μg
NA 160 320 NA 320 >320-640 NA ≥640 ≥640
Fluticasone dipropionate
Hydrofluoroalkane/MDI (44,
110, or 220 μg per puff), μg
176 88-176 88-264 >176-352 >176-352 >264-440 >352mcg >176-352 >440
DPI (50, 100, or 250 μg
per puff), μg
NA 100-200 100-300 NA >200-400 >300-500 NA >200-400 >500
Mometasone DPI (220 μg), μg NA NA 200 NA NA 400 NA NA <400
Triamcinolone acetonide
(75 μg per puff), μg
NA 300-600 300-750 NA >600-900 >750-1500 NA >600-900 >1500
Abbreviations: DPI, dry powder inhaler; MDI, metered-dose inhaler; NA, not
applicable because not approved, not available, no data available, or safety and
efficacy not established in this age group.
a Adapted from the National Asthma Education and Prevention Program.82
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